
Opinion|Videos|May 14, 2025
Common Causes of Bronchiectasis
Panelists discuss how evaluating potential causes of bronchiectasis is important despite many cases being idiopathic, as identifying treatable traits can lead to specific interventions, such as CFTR modulators for those with CF mutations or IgG supplementation.
Advertisement
Episodes in this series

Clinical Brief: Etiologic Evaluation and First-Line Treatment of Bronchiectasis
Main Discussion Topics
- Etiologic evaluation is important, though many cases remain idiopathic.
- Treatment follows both “one-size-fits-all” baseline approaches and targeted interventions based on identified causes.
- First-line treatments focus on airway clearance, hydration, and infection management.
Key Points for Physicians
- Universal approaches include:
- Airway clearance techniques
- Physical exercise/pulmonary rehabilitation
- Regular clinical follow-up
- Nutritional counseling
- Vaccinations
- Etiologic evaluation may identify treatable traits:
- CFTR mutations (potential for modulators)
- Low IgG (consider supplementation)
- Aspiration/reflux (specific management)
- Sinus disease (targeted treatment)
- Personalize approaches based on the patient’s specific presentation and underlying etiology.
Notable Insights
In approximately 40% to 50% of cases, etiologic evaluation can identify host susceptibility factors that allow for targeted interventions beyond general management.
Clinical Significance
Combining universal bronchiectasis management approaches with etiology-specific interventions creates a more effective personalized treatment strategy.
Advertisement
Related to this article

Tammy Lundstrom, MD, JD, discusses the new childhood vaccine order, single-dose MMR access concerns, and the measles resurgence.

Twice-daily dosing of the oral JAK inhibitor deuruxolitinib nearly tripled response rates over once-daily dosing in severe alopecia areata.

Clinicians pair CD20×CD3 bispecifics with radiotherapy in relapsed B‑cell lymphoma, but data stay sparse—early safety signals prompt trials.

Panelists at NASP inSPire2026 said specialty pharmacies could close clinical trial enrollment gaps by capturing one missed data point.

“I think there’s not a lot of information as to what the process is for individuals who have questions about that,” explains Kerry Rogers, MD.

Across 29,132 surgically treated T1 cases, lymph node metastasis hit 19.2% under age 50 vs 11.1% at 50 and older.

Imlunestrant plus abemaciclib doubled median PFS in patients with ESR1-mutated advanced breast cancer.
Advertisement
Advertisement
Trending on AJMC
1
COVID-19 or Flu? Symptoms Alone Can't Tell: Tammy Lundstrom, MD, JD
2
Nearly a Decade After CAR T, Medicare’s Cell and Gene Therapy Payment Gap Persists
3
Twice-Daily Deuruxolitinib Outperformes Once-Daily in Severe AA
4
Perceptions About CGMs Among Primary Care Physicians and Endocrinologists
5

